Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Migraine Disorders HELP
Based on 8,967 articles published since 2009
||||

These are the 8967 published articles about Migraine Disorders that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. 2019

Sacco, Simona / Bendtsen, Lars / Ashina, Messoud / Reuter, Uwe / Terwindt, Gisela / Mitsikostas, Dimos-Dimitrios / Martelletti, Paolo. ·Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, via Vetoio, 67100, L'Aquila, Italy. simona.sacco@univaq.it. · Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. · Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. · 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece. · Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. ·J Headache Pain · Pubmed #30651064.

ABSTRACT: BACKGROUND AND AIM: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention. METHODS: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. RESULTS: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts' opinion. CONCLUSION: Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice.

2 Guideline Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. 2018

Vatzaki, Efstratia / Straus, Sabine / Dogne, Jean-Michel / Garcia Burgos, Juan / Girard, Thomas / Martelletti, Paolo. ·European Medicines Agency, 30 Churchill Place, London, E14 5EU, UK. Efstratia.Vatzaki@ema.europa.eu. · Medicines Evaluation Board, Utrecht, The Netherlands. · PRAC member, European Medicines Agency, London, UK. · Department of Pharmacy, Namur Thrombosis and Haemostasis Centre - Narilis University of Namur, Namur, Belgium. · European Medicines Agency, 30 Churchill Place, London, E14 5EU, UK. · European Headache Federation,. ·J Headache Pain · Pubmed #30109437.

ABSTRACT: Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in the main European Guidelines. Previous (2014) European recommendations on limiting the use of valproate in women of childbearing age did not achieve their objective in terms of limiting the use of valproate in women of childbearing age and raising awareness regarding the hazardous effect of valproate to children exposed in utero. The teratogenic and foetotoxic effects of valproate are well documented, and more recent studies show that there is an even greater neurodevelopmental risk to children exposed to valproate in the womb. The latest 2018 European review from the European Medicines Agency, with the active participation of the European Headache Federation, concluded that not enough has been done to mitigate the risks associated with in utero exposure to valproate. The review called for more extensive restrictions to the conditions for prescribing, better public awareness, and a more effective education campaign in migrainous women.

3 Guideline Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. 2018

Tassorelli, Cristina / Diener, Hans-Christoph / Dodick, David W / Silberstein, Stephen D / Lipton, Richard B / Ashina, Messoud / Becker, Werner J / Ferrari, Michel D / Goadsby, Peter J / Pozo-Rosich, Patricia / Wang, Shuu-Jiun / Anonymous2421236. ·1 Headache Science Center, C. Mondino Foundation, Pavia, Italy. · 2 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. · 3 Department of Neurology, University Hospital Essen, Essen, Germany. · 4 Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. · 5 Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. · 6 Montefiore Headache Center, Department of Neurology and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA. · 7 Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark. · 8 Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. · 9 Hotchkiss Brain Institute, Calgary, Alberta, Canada. · 10 Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. · 11 National Institute for Health Research-Wellcome Trust King's Clinical Research Facility, King's College Hospital, London, England. · 12 Headache Research Group, VHIR, Universitat Autònoma de Barcelona, Barcelona Spain. · 13 Neurology Department, Hospital Vall d'Hebron, Barcelona, Spain. · 14 Neurological Institute, Taipei Veterans General Hospital and Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. ·Cephalalgia · Pubmed #29504482.

ABSTRACT: Background Quality clinical trials form an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. In 2008, the Committee published the first specific guidelines on chronic migraine. Subsequent advances in drug, device, and biologicals development, as well as novel trial designs, have created a need for a revision of the chronic migraine guidelines. Objective The present update is intended to optimize the design of controlled trials of preventive treatment of chronic migraine in adults, and its recommendations do not apply to trials in children or adolescents.

4 Guideline Benign paroxysmal positional vertigo: Diagnostic criteria Consensus document of the Committee for the Classification of Vestibular Disorders of the Bárány Society. 2017

von Brevern, Michael / Bertholon, Pierre / Brandt, Thomas / Fife, Terry / Imai, Takao / Nuti, Daniele / Newman-Toker, David. ·Department of Neurology, Park-Klinik Weissensee, Berlín, Alemania. Electronic address: von.brevern@park-klinik.com. · Department of Otolaryngology, Head and Neck Surgery, Bellvue Hospital, Saint-Etienne, Francia. · Institute of Clinical Neuroscience, Ludwig-Maximilian University, Múnich, Alemania. · Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix, EE. UU. · Department of Otolaryngology, Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka, Japón. · Department of Otolaryngology, Head and Neck Surgery, University of Siena, Siena, Italia. · Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, EE. UU. ·Acta Otorrinolaringol Esp · Pubmed #29056234.

ABSTRACT: This article presents operational diagnostic criteria for benign paroxysmal positional vertigo (BPPV), formulated by the Committee for Classification of Vestibular Disorders of the Bárány Society. The classification reflects current knowledge of clinical aspects and pathomechanisms of BPPV and includes both established and emerging syndromes of BPPV. It is anticipated that growing understanding of the disease will lead to further development of this classification.

5 Guideline Medical Treatment Guidelines for Preventive Treatment of Migraine. 2017

Huang, Tzu-Chou / Lai, Tzu-Hsien / Taiwan Headache Society, Treatment Guideline Subcommittee Of Taiwan Headache Society. · ·Acta Neurol Taiwan · Pubmed #28752512.

ABSTRACT: The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the "start low and go slow" doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.

6 Guideline [Consensus paper of the German Migraine and Headache Society on the structure of headache care facilities in Germany]. 2014

Marziniak, M / Malzacher, V / Förderreuther, S / Jürgens, T / Kropp, P / May, A / Straube, A / Anonymous6330790. ·Neurologische Klinik, Isar-Amper-Klinikum München-Ost, Haar, Deutschland. ·Schmerz · Pubmed #24718744.

ABSTRACT: This consensus paper introduces a classification of headache care facilities on behalf of the German Migraine and Headache Society. This classification is based on the recommendations of the International Association for the Study of Pain (IASP) and the European Headache Federation (EHF) and was adapted to reflect the specific situation of headache care in Germany. It defines three levels of headache care: headache practitioner (level 1), headache outpatient clinic (level 2) and headache centers (level 3). The objective of the publication is to define and establish reliable criteria in the field of headache care in Germany.

7 Guideline [Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)]. 2014

Lantéri-Minet, M / Demarquay, G / Alchaar, H / Bonnin, J / Cornet, P / Douay, X / Dousset, V / Géraud, G / Guillouf, V / Navez, M / Radat, F / Radenne, S / Revol, A / Valade, D / Donnet, A. ·Département d'évaluation et de traitement de la douleur, hôpital Cimiez, bâtiment Mossa, 4, avenue Reine-Victoria, 06000 Nice, France; Inserm/UdA, U1107, Neuro-Dol Clermont-Ferrand, faculté de médecine, BP 38, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France. · Service de neurologie, hôpital de la Croix-Rousse, hospices Civils de Lyon, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. · Cabinet privé, 73, boulevard de Cimiez, 06000 Nice, France. · Cabinet privé, 3, rue Henri Matisse, 91100 Corbeil Essonnes, France. · Cabinet privé, 90, rue Jean-Pierre-Timbaud, 75011 Paris, France. · Cabinet privé, 3, avenue Henri-Delecaux, 59130 Lambersart, France. · Unité de traitement de la douleur chronique, CHU de Bordeaux, 1, place Amélie-Raba-Léon, 33076 Bordeaux, France. · Service de neurologie, hôpital Rangueil, 1, avenue du Pr-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex, France. · Centre d'évaluation et de traitement de la douleur, CHRU, avenue Georges-Clemenceau, 14033 Caen cedex 9, France. · Centre d'évaluation et de traitement de la douleur, hôpital Bellevue, CHU, pavillon 50, 42055 Saint-Étienne, France. · Cabinet privé, 13, place d'Aligre, 75012 Paris, France. · Cabinet privé, 1, chemin du Penthod, 69300 Caluire, France. · Centre urgence céphalées, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. · Inserm/UdA, U1107, Neuro-Dol Clermont-Ferrand, faculté de médecine, BP 38, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France; Centre d'évaluation et de traitement de la douleur, hôpital de la Timone, boulevard Jean-Moulin, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: adonnet@ap-hm.fr. ·Rev Neurol (Paris) · Pubmed #24594364.

ABSTRACT: -- No abstract --

8 Guideline Latin American consensus on guidelines for chronic migraine treatment. 2013

Giacomozzi, Alex Rodrigo Espinoza / Vindas, Alexander Parajeles / Silva, Ariovaldo Alberto da / Bordini, Carlos Alberto / Buonanotte, Carlos Federico / Roesler, Célia Aparecida de Paula / Brito, Cláudio Manoel / Perez, Cristina / Carvalho, Deusvenir de Souza / Macedo, Djacir Dantas Pereira de / Piovesan, Elcio Juliato / Sarmento, Elder Machado / Melhado, Eliana Meire / Éckeli, Fabíola Dach / Kowacs, Fernando / Sobrino, Fidel / Rabello, Getúlio Daré / Rada, Grisel / Souza, Jano Alves de / Casanovas, Juana Rosa / Durán, Juan Carlos / Calia, Leandro Cotoni / Medina, Luis Roberto Partida / Queiroz, Luiz Paulo de / Ciciarelli, Marcelo Cedrinho / Valença, Marcelo Moraes / Cusicanqui, Maria / Jimenez, Maria Karina Velez / Goycochea, Maria Tereza / Peres, Mário Fernando Prieto / Sandoval, Mario Victor Fuentealba / Vincent, Maurice Borges / Gomes, Michel Volcy / Diez, Mónica / Aranaga, Nayeska / Barrientos, Nelson / Kowacs, Pedro André / Filho, Pedro Ferreira Moreira. ·Universidad de Santiago de Chile, Santiago de Chile, Chile. ·Arq Neuropsiquiatr · Pubmed #23857614.

ABSTRACT: Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.

9 Guideline [Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]. 2012

Straube, A / Gaul, C / Förderreuther, S / Kropp, P / Marziniak, M / Evers, S / Jost, W H / Göbel, H / Lampl, C / Sándor, P S / Gantenbein, A R / Diener, H-C / Anonymous930743 / Anonymous940743 / Anonymous950743 / Anonymous960743. ·Neurologische Klinik, Universität München und Oberbayerisches Kopfschmerzzentrum, Marchioninistr. 15, 81377 München, Deutschland. astraube@nefo.med.uni-muenchen.de ·Nervenarzt · Pubmed #23180057.

ABSTRACT: Chronic migraine (CM) was first defined in the second edition of the International Headache Society (IHS) classification in 2004. The definition currently used (IHS 2006) requires the patient to have headache on more than 15 days/month for longer than 3 months and a migraine headache on at least 8 of these monthly headache days and that there is no medication overuse. In daily practice the majority of the patients with CM also report medication overuse but it is difficult to determine whether the use is the cause or the consequence of CM. Most the patients also have other comorbidities, such as depression, anxiety and chronic pain at other locations. Therapy has to take this complexity into consideration and is generally multimodal with behavioral therapy, aerobic training and pharmacotherapy. The use of analgesics should be limited to fewer than 15 days per month and use of triptans to fewer than 10 days per month. Drug treatment should be started with topiramate, the drug with the best scientific evidence. If there is no benefit, onabotulinum toxin A (155-195 Units) should be used. There is also some limited evidence that valproic acid and amitriptyline might be beneficial. Neuromodulation by stimulation of the greater occipital nerve or vagal nerve is being tested in studies and is so far an experimental procedure only.

10 Guideline Canadian Headache Society guideline for migraine prophylaxis. 2012

Pringsheim, Tamara / Davenport, W Jeptha / Mackie, Gordon / Worthington, Irene / Aubé, Michel / Christie, Suzanne N / Gladstone, Jonathan / Becker, Werner J / Anonymous6130728. ·University of Calgary and the Hotchkiss Brain Institute, Calgary, AB, Canada. ·Can J Neurol Sci · Pubmed #22683887.

ABSTRACT: OBJECTIVES: The primary objective of this guideline is to assist the practitioner in choosing an appropriate prophylactic medication for an individual with migraine, based on current evidence in the medical literature and expert consensus. This guideline is focused on patients with episodic migraine (headache on ≤ 14 days a month). METHODS: Through a comprehensive search strategy, randomized, double blind, controlled trials of drug treatments for migraine prophylaxis and relevant Cochrane reviews were identified. Studies were graded according to criteria developed by the US Preventive Services Task Force. Recommendations were graded according to the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. In addition, a general literature review and expert consensus were used for aspects of prophylactic therapy for which randomized controlled trials are not available. RESULTS: Prophylactic drug choice should be based on evidence for efficacy, side-effect profile, migraine clinical features, and co-existing disorders. Based on our review, 11 prophylactic drugs received a strong recommendation for use (topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, butterbur, riboflavin, coenzyme Q10, and magnesium citrate) and 6 received a weak recommendation (divalproex sodium, flunarizine, pizotifen, venlafaxine, verapamil, and lisinopril). Quality of evidence for different medications varied from high to low. Prophylactic treatment strategies were developed to assist the practitioner in selecting a prophylactic drug for specific clinical situations. These strategies included: first time strategies for patients who have not had prophylaxis before (a beta-blocker and a tricyclic strategy), low side effect strategies (including both drug and herbal/vitamin/mineral strategies), a strategy for patients with high body mass index, strategies for patients with co-existent hypertension or with co-existent depression and /or anxiety, and additional monotherapy drug strategies for patients who have failed previous prophylactic trials. Further strategies included a refractory migraine strategy and strategies for prophylaxis during pregnancy and lactation. CONCLUSIONS: There is good evidence from randomized controlled trials for use of a number of different prophylactic medications in patients with migraine. Medication choice for an individual patient requires careful consideration of patient clinical features.

11 Guideline Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. 2012

Holland, S / Silberstein, S D / Freitag, F / Dodick, D W / Argoff, C / Ashman, E / Anonymous2040724. ·Armstrong Atlantic State University, Savannah, GA, USA. ·Neurology · Pubmed #22529203.

ABSTRACT: OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs) or other complementary treatments effective for migraine prevention? METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications for migraine prevention. RESULTS: The author panel reviewed 284 abstracts, which ultimately yielded 49 Class I or Class II articles on migraine prevention; of these 49, 15 were classified as involving nontraditional therapies, NSAIDs, and other complementary therapies that are reviewed herein. RECOMMENDATIONS: Petasites (butterbur) is effective for migraine prevention and should be offered to patients with migraine to reduce the frequency and severity of migraine attacks (Level A). Fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew), magnesium, riboflavin, and subcutaneous histamine are probably effective for migraine prevention (Level B). Treatments considered possibly effective are cyproheptadine, Co-Q10, estrogen, mefenamic acid, and flurbiprofen (Level C). Data are conflicting or inadequate to support or refute use of aspirin, indomethacin, omega-3, or hyperbaric oxygen for migraine prevention. Montelukast is established as probably ineffective for migraine prevention (Level B).

12 Guideline Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. 2012

Silberstein, S D / Holland, S / Freitag, F / Dodick, D W / Argoff, C / Ashman, E / Anonymous2030724. ·Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA. ·Neurology · Pubmed #22529202.

ABSTRACT: OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. RESULTS AND RECOMMENDATIONS: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A).

13 Guideline Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. 2012

Tfelt-Hansen, Peer / Pascual, Julio / Ramadan, Nabih / Dahlöf, Carl / D'Amico, Domenico / Diener, Hans-Christopher / Hansen, Jakob Møller / Lanteri-Minet, Michel / Loder, Elisabeth / McCrory, Douglas / Plancade, Sandra / Schwedt, Todd / Anonymous5150719. ·Danish Headache Center, Department of Neurology, University of Copenhagen, Glostrup, Denmark. ptha@glo.regionh.dk ·Cephalalgia · Pubmed #22384463.

ABSTRACT: -- No abstract --

14 Guideline The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. 2012

Ramasubbu, Rajamannar / Taylor, Valerie H / Samaan, Zainab / Sockalingham, Sanjeev / Li, Madeline / Patten, Scott / Rodin, Gary / Schaffer, Ayal / Beaulieu, Serge / McIntyre, Roger S / Anonymous2380717. ·Department of Psychiatry and Clinical Neurosciences, University of Calgary, Hotchkiss Brain Institute, Calgary, Alberta, Canada. rramasub@ucalgary.ca ·Ann Clin Psychiatry · Pubmed #22303525.

ABSTRACT: BACKGROUND: Medical comorbidity in patients with mood disorders has become an increasingly important clinical and global public health issue. Several specific medical conditions are associated with an increased risk of mood disorders, and conversely, mood disorders are associated with increased morbidity and mortality in patients with specific medical disorders. METHODS: To help understand the bidirectional relationship and to provide an evidence-based framework to guide the treatment of mood disorders that are comorbid with medical illness, we have reviewed relevant articles and reviews published in English-language databases (to April 2011) on the links between mood disorders and several common medical conditions, evaluating the efficacy and safety of pharmacologic and psychosocial treatments. The medical disorders most commonly encountered in adult populations (ie, cardiovascular disease, cerebrovascular disease, cancer, human immunodeficiency virus, hepatitis C virus, migraine, multiple sclerosis, epilepsy, and osteoporosis) were chosen as the focus of this review. RESULTS: Emerging evidence suggests that depression comorbid with several medical disorders is treatable and failure to treat depression in medically ill patients may have a negative effect on medical outcomes. CONCLUSIONS: This review summarizes the available evidence and provides treatment recommendations for the management of comorbid depression in medically ill patients.

15 Guideline Evidence-based guidelines for the chiropractic treatment of adults with headache. 2011

Bryans, Roland / Descarreaux, Martin / Duranleau, Mireille / Marcoux, Henri / Potter, Brock / Ruegg, Rick / Shaw, Lynn / Watkin, Robert / White, Eleanor. ·Guidelines Development Committee Chair and Chiropractor, Private Practice, Clarenville, Newfoundland and Labrador, Canada. rbryans@nfld.net ·J Manipulative Physiol Ther · Pubmed #21640251.

ABSTRACT: OBJECTIVE: The purpose of this manuscript is to provide evidence-informed practice recommendations for the chiropractic treatment of headache in adults. METHODS: Systematic literature searches of controlled clinical trials published through August 2009 relevant to chiropractic practice were conducted using the databases MEDLINE; EMBASE; Allied and Complementary Medicine; the Cumulative Index to Nursing and Allied Health Literature; Manual, Alternative, and Natural Therapy Index System; Alt HealthWatch; Index to Chiropractic Literature; and the Cochrane Library. The number, quality, and consistency of findings were considered to assign an overall strength of evidence (strong, moderate, limited, or conflicting) and to formulate practice recommendations. RESULTS: Twenty-one articles met inclusion criteria and were used to develop recommendations. Evidence did not exceed a moderate level. For migraine, spinal manipulation and multimodal multidisciplinary interventions including massage are recommended for management of patients with episodic or chronic migraine. For tension-type headache, spinal manipulation cannot be recommended for the management of episodic tension-type headache. A recommendation cannot be made for or against the use of spinal manipulation for patients with chronic tension-type headache. Low-load craniocervical mobilization may be beneficial for longer term management of patients with episodic or chronic tension-type headaches. For cervicogenic headache, spinal manipulation is recommended. Joint mobilization or deep neck flexor exercises may improve symptoms. There is no consistently additive benefit of combining joint mobilization and deep neck flexor exercises for patients with cervicogenic headache. Adverse events were not addressed in most clinical trials; and if they were, there were none or they were minor. CONCLUSIONS: Evidence suggests that chiropractic care, including spinal manipulation, improves migraine and cervicogenic headaches. The type, frequency, dosage, and duration of treatment(s) should be based on guideline recommendations, clinical experience, and findings. Evidence for the use of spinal manipulation as an isolated intervention for patients with tension-type headache remains equivocal.

16 Guideline Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). 2011

Haag, Gunther / Diener, Hans-Christoph / May, Arne / Meyer, Christian / Morck, Hartmut / Straube, Andreas / Wessely, Peter / Evers, Stefan / Anonymous2880682 / Anonymous2890682 / Anonymous2900682 / Anonymous2910682. ·Michael-Balint-Klinik, Königsfeld, Germany. guntherhaag@hotmail.com ·J Headache Pain · Pubmed #21181425.

ABSTRACT: The current evidence-based guideline on self-medication in migraine and tension-type headache of the German, Austrian and Swiss headache societies and the German Society of Neurology is addressed to physicians engaged in primary care as well as pharmacists and patients. The guideline is especially concerned with the description of the methodology used, the selection process of the literature used and which evidence the recommendations are based upon. The following recommendations about self-medication in migraine attacks can be made: The efficacy of the fixed-dose combination of acetaminophen, acetylsalicylic acid and caffeine and the monotherapies with ibuprofen or naratriptan or acetaminophen or phenazone are scientifically proven and recommended as first-line therapy. None of the substances used in self-medication in migraine prophylaxis can be seen as effective. Concerning the self-medication in tension-type headache, the following therapies can be recommended as first-line therapy: the fixed-dose combination of acetaminophen, acetylsalicylic acid and caffeine as well as the fixed combination of acetaminophen and caffeine as well as the monotherapies with ibuprofen or acetylsalicylic acid or diclofenac. The four scientific societies hope that this guideline will help to improve the treatment of headaches which largely is initiated by the patients themselves without any consultation with their physicians.

17 Guideline [French guidelines for the pharmacological treatment of acute and chronic pain in children]. 2010

Annequin, D. ·Unité Fonctionnelle de lutte Contre la Douleur Hôpital d'Enfants Armand-Trousseau, 75012 Paris, France. daniel.annequin@trs.aphp.fr ·Arch Pediatr · Pubmed #20654831.

ABSTRACT: -- No abstract --

18 Guideline EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. 2010

Burgunder, J-M / Finsterer, J / Szolnoki, Z / Fontaine, B / Baets, J / Van Broeckhoven, C / Di Donato, S / De Jonghe, P / Lynch, T / Mariotti, C / Schöls, L / Spinazzola, A / Tabrizi, S J / Tallaksen, C / Zeviani, M / Harbo, H F / Gasser, T / Anonymous3010655. ·Department of Neurology, University of Bern, Bern, Switzerland. Jean-marc.burgunder@dkf.unibe.ch ·Eur J Neurol · Pubmed #20298421.

ABSTRACT: OBJECTIVES: These EFNS guidelines on the molecular diagnosis of channelopathies, including epilepsy and migraine, as well as stroke, and dementia are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated. SEARCH STRATEGY: To collect data about planning, conditions, and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers, and guideline recommendations were reviewed. RESULTS: The best level of evidence for genetic testing recommendation (B) can be found for a small number of syndromes, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, severe myoclonic epilepsy of infancy, familial recurrent hemorrhages, familial Alzheimer's disease, and frontotemporal lobar degeneration. Good practice points can be formulated for a number of other disorders. CONCLUSION: These guidelines are provisional, and the future availability of molecular genetic epidemiological data about the neurogenetic disorders under discussion in our article will allow improved recommendation with an increased level of evidence.

19 Guideline EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. 2009

Evers, S / Afra, J / Frese, A / Goadsby, P J / Linde, M / May, A / Sándor, P S / Anonymous120637. ·Department of Neurology, University of Münster, Münster, Germany. everss@uni-muenster.de ·Eur J Neurol · Pubmed #19708964.

ABSTRACT: BACKGROUND: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life. OBJECTIVES: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel. METHODS: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points. RECOMMENDATIONS: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.

20 Editorial Foreword: Special Collection on Sleep Disorders and Migraine. 2018

Smitherman, Todd A. ·Department of Psychology, Migraine and Behavioral Health Laboratory, University of Mississippi, Oxford, MS, USA. ·Headache · Pubmed #30152163.

ABSTRACT: -- No abstract --

21 Editorial IV Lidocaine for Status Migraine: Making an "Off-Label" Treatment Decision. 2018

Tasker, Robert C. ·Department of Anesthesia, Critical Care and Pain Medicine; and Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA. ·Pediatr Crit Care Med · Pubmed #30095718.

ABSTRACT: -- No abstract --

22 Editorial Migraine disability complicated by medication overuse. 2018

Martelletti, P. ·Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. ·Eur J Neurol · Pubmed #29938876.

ABSTRACT: -- No abstract --

23 Editorial The evolution of migraine therapy: a new concept of care. 2018

Frediani, Fabio. ·Headache Center, Neurological and Stroke Unit, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Via Pio II, 3, 20153, Milan, Italy. fabio.frediani@asst-santipaolocarlo.it. ·Neurol Sci · Pubmed #29904880.

ABSTRACT: -- No abstract --

24 Editorial New preventive treatments for migraine. 2018

Burch, Rebecca / Rayhill, Melissa. ·Harvard Medical School Boston, Massachusetts, USA. · Jacobs School of Medicine and Biomedical Sciences State University of New York, Buffalo, New York, USA. ·BMJ · Pubmed #29899031.

ABSTRACT: -- No abstract --

25 Editorial Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea. 2018

Loder, Elizabeth W / Robbins, Matthew S. ·Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Jack D. Weiler Hospital, Montefiore Medical Center, Inpatient Services, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York. ·JAMA · Pubmed #29800193.

ABSTRACT: -- No abstract --

Next